➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Johnson and Johnson
Merck
Moodys
Baxter

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,153,635

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,153,635
Title: Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
Abstract:A method for treating vulvovaginal candidiasis including the steps of: (a) administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally; and (b) applying miconazole nitrate in a pharmaceutically acceptable carrier to the vulva. Also a kit for the treatment of vulvovaginal candidiasis including: (a) a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier and in a form adapted to be administered intra-vaginally; and (b) an amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva.
Inventor(s): Upmalis; David H. (Newtown, PA)
Assignee:
Application Number:09/197,019
Patent Claims: 1. A method for treating vulvovaginal candidiasis consisting essentially of the steps of:

(a) administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally; and

(b) applying topically miconazole nitrate in a pharmaceutically acceptable carrier to the vulva.

2. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises about 400 to about 2000 mg of miconazole nitrate.

3. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises about 600 to about 1200 mg of miconazole nitrate.

4. The method of claim 1, wherein the single dose of miconazole nitrate administered intra-vaginally comprises 2.5 g of 16% miconazole nitrate cream, 5 g of 8% miconazole nitrate cream, 5 g 12% miconazole nitrate cream or 5 g 16% miconazole nitrate cream.

5. The method of claim 1, wherein step (b) is performed 1-2 times per day.

6. The method of claim 1, wherein step (b) is performed 1-2 times per day for about 7 days.

7. The method of claim 3, wherein step (b) is performed 1-2 times per day for about 7 days.

8. A kit for the treatment of vulvovaginal candidiasis consisting essentially of:

(a) a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier and in a form adapted to be administered intra-vaginally; and

(b) an amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva.

9. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises about 400 to about 2000 mg of miconazole nitrate.

10. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises about 600 to about 1200 mg of miconazole nitrate.

11. The kit of claim 8, wherein the single dose of miconazole nitrate adapted to be administered intra-vaginally comprises 2.5 g of 16% miconazole nitrate cream, 5 g of 8% miconazole nitrate cream, 5 g 12% miconazole nitrate cream or 5 g 16% miconazole nitrate cream.

12. The kit of claim 8, wherein the amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva is a sufficient amount to be applied 1-2 times per day for about 7 days.

13. The kit of claim 10, wherein the amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva is a sufficient amount to be applied 1-2 times per day for about 7 days.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Medtronic
Dow
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.